Drugs & Targets FDA grants Orphan Drug Designation to Reolysin in pancreatic cancer February 20, 2015Vol.41 No.07
Drugs & Targets FDA expands indication for Revlimid to include multiple myeloma February 20, 2015Vol.41 No.07
Drugs & Targets E.U. Expands Velcade Label; ODAC to Examine Talimogene Laherparepvec in Melanoma February 13, 2015Vol.41 No.06
Drugs & Targets Merck to assume full responsibility for Erbitux in Japan from Bristol Myers-Squibb February 13, 2015Vol.41 No.06
Drugs & Targets MPDL3280A receives second breakthrough therapy designation February 06, 2015Vol.41 No.05
Drugs & Targets FDA Grants Accelerated Approval To Ibrance in Breast Cancer February 06, 2015Vol.41 No.05
